A genome-wide association study of antidepressant-induced mania.
Antidepressant-induced mania
Bipolar disorder
Depression
Genome-wide association study
Pharmacogenetics
Journal
Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617
Informations de publication
Date de publication:
20 12 2023
20 12 2023
Historique:
received:
25
01
2023
revised:
20
05
2023
accepted:
21
05
2023
medline:
7
9
2023
pubmed:
27
5
2023
entrez:
26
5
2023
Statut:
ppublish
Résumé
Antidepressant-induced mania (AIM) is a side effect of antidepressant treatment that is characterized by mania or hypomania after the start of medication. It is likely polygenic, but its genetic component remains largely unexplored. We aim to conduct the first genome-wide association study of AIM in 814 bipolar disorder patients of European ancestry. We report no significant findings from our single-marker or gene-based analyses. Our polygenic risk score analyses also did not yield significant results with bipolar disorder, antidepressant response, or lithium response. Our suggestive findings on the hypothalamic-pituitary-adrenal axis and the opioid system in AIM require independent replications.
Identifiants
pubmed: 37236419
pii: S0278-5846(23)00086-6
doi: 10.1016/j.pnpbp.2023.110800
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110800Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest CCZ, AKT, and JLK hold patents for genetic markers related to psychotropic medication outcomes. JLK is a member of the Scientific Advisory Board of Myriad Neuroscience. The other authors reported no conflicts of interest related to this study.